VIR — Vir Biotechnology, Inc.

Summary of Vir Biotechnology's Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• R&D Expenses: $151.5 million, down from $195.2 million in Q3 2024, primarily due to lower licensing expenses and cost savings from restructuring.
• SG&A Expenses: $22.2 million, decreased from $25.7 million in Q3 2024, reflecting operational efficiencies.
• Total Operating Expenses: $173.7 million, a decrease of $46.2 million year-over-year.
• Net Loss: $163.1 million, improved from a net loss of $213.7 million in Q3 2024.
• Cash Position: Ended the quarter with approximately $810.7 million in cash, cash equivalents, and investments, with a projected cash runway extending into mid-2027.

2. Strategic Updates and Business Highlights

• Hepatitis Delta Program:

  • Completed enrollment in ECLIPSE 1, a pivotal Phase III study, ahead of schedule.
  • ECLIPSE 2 is progressing well in Europe, and ECLIPSE 3 is on track to provide comparative data against bulevirtide.
  • Upcoming presentation of SOLSTICE 48-week data at AASLD on November 9, expected to reinforce the efficacy of their combination regimen.

• Oncology Portfolio:

  • Dosed the first patient in a combination study for VIR-5500, a PSMA-targeted T-cell engager.
  • Continued progress in dose escalation for VIR-5818 and VIR-5525.
  • Plans to provide a comprehensive data update for VIR-5500 in Q1 2026.

3. Forward Guidance and Outlook

• Hepatitis Delta: Expect primary completion for ECLIPSE 1 in Q4 2026 and top-line data for all ECLIPSE studies by Q1 2027.
• Oncology: Anticipate a significant update for VIR-5500 in Q1 2026, including data on safety and efficacy measures.
• Overall Strategy: Focus on advancing registrational studies and oncology programs while maintaining a strong cash position to support ongoing operations.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Gilead's upcoming launch of bulevirtide could impact market dynamics, although management views it as a potential benefit for increasing disease awareness.
• Clinical Risks: The company has not yet reached the maximum tolerated dose for VIR-5500, raising questions about the dose escalation process and potential safety concerns.
• Market Adoption: The need for robust clinical data to differentiate their products in a competitive landscape, particularly in the oncology space, remains critical.

5. Notable Q&A Insights

• VIR-5500 Differentiation: Management emphasized the unique dual-masking approach of the PRO-XTEN platform, which they believe will enhance the therapeutic index and durability of responses.
• HDV Program Expectations: The combination therapy's ability to suppress HDV RNA and reduce hepatitis B surface antigen levels is seen as a significant differentiator, with strong KOL support anticipated.
• Patient Population for HDV: The company estimates a broad addressable population of approximately 60,000 viremic patients in the U.S., with strategies in place to enhance patient awareness and identification ahead of their product launch.

Overall, Vir Biotechnology reported a strong quarter with significant progress in clinical programs and a solid financial foundation, while navigating competitive pressures and clinical challenges.